OATD-02

• Description :

  OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study[1].

• UNSPSC :

  12352211

• Target :

  Arginase

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/oatd-02.html

• Solubility :

  10 mM in DMSO

• Smiles :

  N[C@]1(C(O)=O)C[C@H](CCB(O)O)CC[C@H]1CN(C)C

• Molecular Formula :

  C12H25BN2O4

• Molecular Weight :

  272.15

• References & Citations :

  [1]Borek B, et al. Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy. Mol Cancer Ther. 2023;22 (7) :807-817.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [2146132-73-0]